RogerKennethCadyMD

Family Medicine • Springfield, MO

Headache Medicine

CEO at Headache Care Center and Vice President of Neurology, Alder BioPharmaceuticals

Join to view full profile

Dr. Cady is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cady's full profile

Already have an account?

Office
3805 S Kansas Expy
Springfield, MO 65807
Phone+1 417-890-7888

Fax+1 417-890-8827

Education & Training

Mayo Clinic College of Medicine and Science (La Crosse)Residency, Family Medicine, 1977 - 1980
Mayo Clinic College of MedicineClass of 1977

Certifications & Licensure

MO State Medical License 1986 - 2025
WA State Medical License 2017 - 2021
WI State Medical License 1978 - 2017

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers Start of enrollment: 2004 May 01
Completed
Phase 4
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine. Start of enrollment: 2005 Dec 01
Completed
Phase 2
Two Rizatriptan Prescribing Portions for Treatment of Migraine Start of enrollment: 2006 Dec 01
Completed
Phase 4
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction Start of enrollment: 2006 Oct 01
Terminated
Phase 4
Staccato Prochlorperazine in Migraine (in Clinic) Start of enrollment: 2005 Mar 01
Completed
Phase 2
The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines Start of enrollment: 2008 Aug 01
Completed
Phase 2
Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine Start of enrollment: 2008 Feb 01
Completed
Staccato Loxapine in Migraine (Out Patient) Start of enrollment: 2009 Jan 01
Completed
Phase 2
Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine Start of enrollment: 2009 Aug 01
Completed
Phase 4
"Completeness of Response" Following Treatment With Treximet™ for Migraine Start of enrollment: 2009 Jun 01
Completed
Phase 4
Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction Start of enrollment: 2010 May 01
Terminated
Phase 4
Calcitonin Gene-related Peptide Levels in Chronic Migraine Start of enrollment: 2010 Jun 01
Completed
Phase 4
Treximet in the Treatment of Chronic Migraine Start of enrollment: 2010 Sep 01
Completed
Phase 4
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine Start of enrollment: 2010 Dec 01
Completed
Phase 4
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet Start of enrollment: 2011 May 01
Completed
Phase 4
A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines Start of enrollment: 2013 Apr 01
Completed
Phase 2
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine Start of enrollment: 2014 Apr 01
Completed
Phase 4
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache Start of enrollment: 2014 Jul 07
Completed
Phase 2
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine Start of enrollment: 2014 Aug 01
Completed
Phase 2
Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches Start of enrollment: 2014 Jul 01
Completed
Phase 2
A Study of Galcanezumab in Participants With Chronic Cluster Headache Start of enrollment: 2015 Jun 18
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

38 citations
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase Activating Peptide
Cristina Moldovan Loomis, Benjamin H. Dutzar, Ethan W. Ojala, Lee Hendrix, Charlie Karasek
The Journal of Pharmacology and Experimental Therapeutics. 2019-01-14
7 citations
Qualitative Change in Migraine Prevention
Roger Cady, Richard B. Lipton
Headache. 2018-07-01
18 citations
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute trea...
Sagar Munjal, Elimor Brand-Schieber, Kent Allenby, Egilius L.H. Spierings, Roger Cady
The Journal of Headache and Pain. 2017-03-01

Journal Articles

Qualitative Change in Migraine Prevention?
Richard B Lipton, Roger Cady, Headache: The Journal of Head and Face Pain

Lectures

InjectionED: Advanced Injection Training for Pain Disorders of the Head, Neck & Face
Cvent Online Event Registration Software, San Diego, California - 12/1/2012
2012 Best Practices in Primary Care
Primary Care Education, Irving, Texas - 6/29/2012

Press Mentions

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTIApril 2nd, 2022
Migraine and Genetics: Largest Study to Date May Inspire New TreatmentsFebruary 15th, 2022
Migraine Prevention Drug Eptinezumab Shows Efficacy in Treating Acute AttacksJune 16th, 2021
Join now to see all

Professional Memberships

American Academy of Pain Medicine - AAPM
Member